The Prescription for Pharma Is Revenue Growth
Despite the hullabaloo about health-care reform, investors still reward revenue growth by pharmaceutical companies. But that growth requires organic and acquisitive reinvestment.
By Gregory V. Milano and John R. Cryan | April 4, 2012